Sabine Adam-Klages
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sabine Adam-Klages has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Dieter Kabelitz
Universitätsklinikum Schleswig-Holstein Campus Kiel
2 shared publications- Dieter Kabelitz
Institute of Immunology, Christian-Albrechts University Kiel, Kiel, Germany
2 shared publications - Ottmar Janssen
Molecular Immunology—Institute for Immunology, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany
2 shared publications Sandra Ussat
Institut für Immunologie, Christian-Albrechts-Universität Kiel, 24105, Kiel, Germany
2 shared publicationsUlf-Eike Werner
Institut für Immunologie, Christian-Albrechts-Universität Kiel, 24105 Kiel, Germany
2 shared publications- Anja Koop
Institute for Immunology, University Hospital Schleswig-Holstein Campus Kiel, Arnold-Heller-Str. 3, Bldg 17, Kiel, 24105, Germany
1 shared publication
Latest Publications
- 1 April 2018
- Published by Elsevier in Cellular Immunology
- Vol. 326, 60-67
TLR-induced immunomodulatory cytokine expression by human gingival stem/progenitor cells
- 1 April 2018
- Published by Elsevier in Cellular Immunology
- Vol. 326, 60-67
TLR-induced immunomodulatory cytokine expression by human gingival stem/progenitor cells
- Open Access
- 17 December 2014
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 5, 643
Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy
The success of gammadelta (gd) T cell-based immunotherapy, where the cytotoxic activity of circulating gd T lymphocytes is activated by nitrogen-containing bisphosphonates (n-BP), or possibly by bispecific antibodies or the combination of both, requires a profound knowledge of patients´ gd T cells. A possible influence of radio- or chemotherapy on gd T cells as well as their reported exhaustion after repetitive treatment with n-BP or their lack of response to various cancers can be easily determined by the monitoring assays described in this perspective article. Monitoring the absolute cell numbers of circulating gd T cell subpopulations in small volumes of whole blood from cancer patients and determining gd T cell-cytotoxicity using the Real-Time Cell Analyzer can give a more comprehensive assessment of a personalized tumor treatment. Possible future directions such as the combined usage of n-BP or phosphorylated antigens together with bispecific antibodies that selectively target gd T cells to tumor associated antigens, will be discussed. Such strategies induce expansion and enhance gd T cell-cytotoxicity and might possibly avoid their exhaustion and overcome the immunosuppressive tumor microenvironment.
- 17 December 2014
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 5, 643
Open AccessMonitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy
The success of gammadelta (gd) T cell-based immunotherapy, where the cytotoxic activity of circulating gd T lymphocytes is activated by nitrogen-containing bisphosphonates (n-BP), or possibly by bispecific antibodies or the combination of both, requires a profound knowledge of patients´ gd T cells. A possible influence of radio- or chemotherapy on gd T cells as well as their reported exhaustion after repetitive treatment with n-BP or their lack of response to various cancers can be easily determined by the monitoring assays described in this perspective article. Monitoring the absolute cell numbers of circulating gd T cell subpopulations in small volumes of whole blood from cancer patients and determining gd T cell-cytotoxicity using the Real-Time Cell Analyzer can give a more comprehensive assessment of a personalized tumor treatment. Possible future directions such as the combined usage of n-BP or phosphorylated antigens together with bispecific antibodies that selectively target gd T cells to tumor associated antigens, will be discussed. Such strategies induce expansion and enhance gd T cell-cytotoxicity and might possibly avoid their exhaustion and overcome the immunosuppressive tumor microenvironment.
- Open Access
- 10 June 2013
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 11 (1) , 41
Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration
Background: Due to their restricted expression in male germ cells and certain tumors, cancer/testis (CT) antigens are regarded as promising targets for tumor therapy. CT45 is a recently identified nuclear CT antigen that was associated with a severe disease score in Hodgkin’s lymphoma and poor prognosis in multiple myeloma. As for many CT antigens, the biological function of CT45 in developing germ cells and in tumor cells is largely unknown. Methods: CT45 expression was down-regulated in CT45-positive Hodgkin’s lymphoma (L428), fibrosarcoma (HT1080) and myeloma (U266B1) cells using RNA interference. An efficient CT45 knock-down was confirmed by immunofluorescence staining and/or Western blotting. These cellular systems allowed us to analyze the impact of CT45 down-regulation on proliferation, cell cycle progression, morphology, adhesion, migration and invasive capacity of tumor cells. Results: Reduced levels of CT45 did not coincide with changes in cell cycle progression or proliferation. However, we observed alterations in cell adherence, morphology and migration/invasion after CT45 down-regulation. Significant changes in the distribution of cytoskeleton-associated proteins were detected by confocal imaging. Changes in cell adherence were recorded in real-time using the xCelligence system with control and siRNA-treated cells. Altered migratory and invasive capacity of CT45 siRNA-treated cells were visualized in 3D migration and invasion assays. Moreover, we found that CT45 down-regulation altered the level of the heterogeneous nuclear ribonucleoprotein syncrip (hnRNP-Q1) which is known to be involved in the control of focal adhesion formation and cell motility. Conclusions: Providing first evidence of a cell biological function of CT45, we suggest that this cancer/testis antigen is involved in the modulation of cell morphology, cell adherence and cell motility. Enhanced motility and/or invasiveness of CT45-positive cells could contribute to the more severe disease progression that is correlated to CT45-positivity in several malignancies.
- 10 June 2013
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 11 (1) , 41
Open AccessDown-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration
Background: Due to their restricted expression in male germ cells and certain tumors, cancer/testis (CT) antigens are regarded as promising targets for tumor therapy. CT45 is a recently identified nuclear CT antigen that was associated with a severe disease score in Hodgkin’s lymphoma and poor prognosis in multiple myeloma. As for many CT antigens, the biological function of CT45 in developing germ cells and in tumor cells is largely unknown. Methods: CT45 expression was down-regulated in CT45-positive Hodgkin’s lymphoma (L428), fibrosarcoma (HT1080) and myeloma (U266B1) cells using RNA interference. An efficient CT45 knock-down was confirmed by immunofluorescence staining and/or Western blotting. These cellular systems allowed us to analyze the impact of CT45 down-regulation on proliferation, cell cycle progression, morphology, adhesion, migration and invasive capacity of tumor cells. Results: Reduced levels of CT45 did not coincide with changes in cell cycle progression or proliferation. However, we observed alterations in cell adherence, morphology and migration/invasion after CT45 down-regulation. Significant changes in the distribution of cytoskeleton-associated proteins were detected by confocal imaging. Changes in cell adherence were recorded in real-time using the xCelligence system with control and siRNA-treated cells. Altered migratory and invasive capacity of CT45 siRNA-treated cells were visualized in 3D migration and invasion assays. Moreover, we found that CT45 down-regulation altered the level of the heterogeneous nuclear ribonucleoprotein syncrip (hnRNP-Q1) which is known to be involved in the control of focal adhesion formation and cell motility. Conclusions: Providing first evidence of a cell biological function of CT45, we suggest that this cancer/testis antigen is involved in the modulation of cell morphology, cell adherence and cell motility. Enhanced motility and/or invasiveness of CT45-positive cells could contribute to the more severe disease progression that is correlated to CT45-positivity in several malignancies.
- 12 December 2005
- Published by Wiley in Signal Transduction
- Vol. 5 (6) , 350-355
Caspases and proliferation
Cysteine‐proteases belonging to the family of caspases have been described as central executioners of apoptotic signals. The relevance of apoptosis in T cell homeostasis is primarily defined by the necessity to quickly and efficiently eliminate effector T lymphocytes subsequent to clonal expansion and differentiation. This process is executed through the activation of caspases. Apoptosis can be initiated by interaction of the death receptor Fas with its ligand, triggering a signaling cascade comprising Fas‐associated death domain protein (FADD), caspase‐8 and caspase‐3, culminating in cell death. Surprisingly, emerging evidence suggests a contribution of these molecules also in non‐apoptotic and even proliferative signals. The potentially dual role of caspases does not seem to be restricted to T cells but is observed in other cells of the hematopoietic lineage as well. A block of the FADD/caspase‐signaling pathway, either by inserting mutations or by using pharmacological inhibitors, not only leads to resistance of cells to apoptotic stimuli, but also negatively affects growth responses. Despite large research effort, the exact molecular mechanism how caspases mediate proliferation remains to be clarified. This review summarizes facts and hypotheses about potential junctions, coupling the opposing signals leading to death or proliferation and discusses, under which circumstances active caspases might confer to either pathway.
- 12 December 2005
- Published by Wiley in Signal Transduction
- Vol. 5 (6) , 350-355
Caspases and proliferation
Cysteine‐proteases belonging to the family of caspases have been described as central executioners of apoptotic signals. The relevance of apoptosis in T cell homeostasis is primarily defined by the necessity to quickly and efficiently eliminate effector T lymphocytes subsequent to clonal expansion and differentiation. This process is executed through the activation of caspases. Apoptosis can be initiated by interaction of the death receptor Fas with its ligand, triggering a signaling cascade comprising Fas‐associated death domain protein (FADD), caspase‐8 and caspase‐3, culminating in cell death. Surprisingly, emerging evidence suggests a contribution of these molecules also in non‐apoptotic and even proliferative signals. The potentially dual role of caspases does not seem to be restricted to T cells but is observed in other cells of the hematopoietic lineage as well. A block of the FADD/caspase‐signaling pathway, either by inserting mutations or by using pharmacological inhibitors, not only leads to resistance of cells to apoptotic stimuli, but also negatively affects growth responses. Despite large research effort, the exact molecular mechanism how caspases mediate proliferation remains to be clarified. This review summarizes facts and hypotheses about potential junctions, coupling the opposing signals leading to death or proliferation and discusses, under which circumstances active caspases might confer to either pathway.
- 1 January 2005
- Published by Springer Nature in Immunologic Research
- Vol. 33 (2) , 149-166
Death Receptors and Caspases: Role in Lymphocyte Proliferation, Cell Death, and Autoimmunity
The role of death receptors and caspases as mediators of programmed cell death is well established. This review focuses on new insights into alternative functions of these molecules in activation and...
- 1 January 2005
- Published by Springer Nature in Immunologic Research
- Vol. 33 (2) , 149-166
Death Receptors and Caspases: Role in Lymphocyte Proliferation, Cell Death, and Autoimmunity
The role of death receptors and caspases as mediators of programmed cell death is well established. This review focuses on new insights into alternative functions of these molecules in activation and...
- 25 September 2002
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 297 (5) , 1186-1190
Species-specific differences in the usage of several caspase substrates
- 25 September 2002
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 297 (5) , 1186-1190
Species-specific differences in the usage of several caspase substrates
- 14 June 2002
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 294 (3) , 672-679
Upregulation of p21WAF1/Cip1 precedes tumor necrosis factor-induced necrosis-like cell death
- 14 June 2002
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 294 (3) , 672-679
Upregulation of p21WAF1/Cip1 precedes tumor necrosis factor-induced necrosis-like cell death